Company intelligence / Profile preview
AVEO Oncology
Boston, Massachusetts, United Statesaveooncology.com ↗
- Ownership
- Public · 051910.KS
- Development stage
- Commercial
01
Overview
AVEO's lead product FOTIVDA (tivozanib) received FDA approval on March 10, 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma following two or more prior systemic therapies. The company has multiple clinical trials ongoing, including combination studies of tivozanib with immunotherapy agents.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small moleculesMonoclonal antibodies (mAbs)IgG1 antibodies
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on AVEO Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVEO Oncology.